Description:
Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Check for active clinical trials or closed clinical trials using this agent.
- Molecular Weight: 454.86
- Molecular Formula: C22H19ClN4O5
Purity: ≥95%
Canonical SMILES:
CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
InChI:
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChIKey: SPMVMDHWKHCIDT-UHFFFAOYSA-N
- Boiling Point: 550.4±50.0 °C at 760 mmHg
- Melting Point: >202 °C (dec.)
- Solubility: Soluble in DMSO (Slightly), Methanol (Slightly)
- Appearance: Light beige to light brown to white powder
- Storage: Store at 2-8 °C, sealed storage, away from moisture and light
Synonyms:
AV-951; AV951; AV 951; KRN951; KRN 951; KRN-951; Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-; N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea; Fotivda; Kil 8951; Tivozanib
More details are to be found on supplier website
